CE Information and Faculty Disclosures

• TARGET AUDIENCE
  These activities are intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).
  
  LEARNING OBJECTIVES

  • Individualize the selection of systemic therapy for patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile, coexisting medical conditions, psychosocial status and, where applicable, prior therapeutic exposure.​
  • Recognize the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and discern how this strategy can be optimally integrated into nonresearch treatment.​
  • Compare and contrast the efficacy and safety of approved BTK inhibitors for the treatment of CLL to identify patients for whom each of these agents may be appropriate.​
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current clinical practice.​
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies in the management of CLL.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Presenting Faculty Members
  
  Ian W Flinn, MD, PhD
  Director of Lymphoma Research Program
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seagen Inc, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seagen Inc, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc.
  
  John M Pagel, MD, PhD
  Chief of Hematologic Malignancies
  Center for Blood Disorders and Stem Cell Transplantation
  Swedish Cancer Institute
  Seattle, Washington
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Gilead Sciences Inc, MorphoSys, Seagen Inc.
  
  Tanya Siddiqi, MD
  Associate Professor
  Director, Chronic Lymphocytic Leukemia Program
  Department of Hematology and Hematopoietic Cell Transplantation
  City of Hope National Medical Center
  Duarte, California
  
  Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene Ltd; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.
  
  Contributing General Medical Oncologists
  
  Gigi Chen, MD
  Diablo Valley Oncology and Hematology Medical Group
  Pleasant Hill, California
  
  No relevant conflicts of interest to disclose.
  
  Ranju Gupta, MD
  Attending Physician
  Co-Director, Cardio-Oncology Program
  LVPG Hematology Oncology Associates
  Lehigh Valley Health Network
  Bethlehem, Pennsylvania
  
  Speakers Bureau: Lilly.
  
  Laurie Matt-Amaral, MD, MPH
  Attending Physician
  Cleveland Clinic Akron General Medical Center
  Akron, Ohio
  
  Speakers Bureau: Bristol-Myers Squibb Company.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.
  
  Release date: May 2021
  Expiration date: May 2022